Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degenerati…

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no ...
Fierce Biotech

Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Geek Culture

‘Yakuza Kiwami 3 & Dark Ties’ Breathes New Life Into Ageing 2009 Title With Fresh Gameplay Additions

Yakuza Kiwami 3 and Dark Ties brings a host of gameplay tweaks and new additions to address the criticisms of the original ...
Ophthalmology Times

Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...